Evolution of regulatory frameworks

Nature Reviews Drug Discovery

Volumn 10, Issue 1, 2011, Pages 3-4

  Breckenridge, Alasdair ^a   Feldschreiber, Peter ^a   Gregor, Simon ^a   Raine, June ^a   Mulcahy, Leigh Ann ^b  

^a MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL RESEARCH; CONTRACEPTION; DATA BASE; DRUG DEVELOPMENT; DRUG RESEARCH; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EUROPE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; LAW; MEDICINE; NOTE; POLICY; PRIORITY JOURNAL; PUBLIC HEALTH; TECHNOLOGY; UNITED STATES; VENOUS THROMBOEMBOLISM;

DRUG AND NARCOTIC CONTROL; DRUG DESIGN; GOVERNMENT AGENCIES; GOVERNMENT REGULATION; HUMANS; PHARMACEUTICAL PREPARATIONS; PUBLIC HEALTH;

EID: 78650819372     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3348     Document Type: Note

References (6)

1. Regnstrom, J. et al. Factors associated with success of marketing authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency. Eur. J. Clin. Pharmacol. 66, 39-48 (2010).
2. US FDA. Adaptive design clinical trials for drugs and biologics. FDA [online], http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM201790. pdf (2010).
3. Wise, L. et al. New approaches to drug safety: a pharmacovigilance toolkit. Nature Rev. Drug Discov. 8, 779-782 (2009).
4. Eichler, H. G. et al. Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma. Nature Rev. Drug Discov. 7, 818-826 (2008).
5. Eichler, H. G. et al. Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers. Nature Rev. Drug Discov. 9, 277-291 (2010).
6. US FDA. Advancing regulatory science for public health. FDA [online], http://www.fda.gov/ScienceResearch/SpecialTopics/RegulatoryScience/ ucm228131.htm (2010).